List view / Grid view
History has demonstrated that the use of companion in vitro diagnostic tests to select cancer patients positive for a drug target significantly improves response to targeted anti-cancer therapies...
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Allergy Therapeutics has announced the publication of a key paper and featured article in the World Allergy Journal about proteomics in the field of allergy...
Cancer cells are addicted to glucose and glutamine, which enables them to generate the energy and macromolecule synthesis intermediates to support their growth...
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
7 May 2015 | By Victoria White
Pfizer has made two strategic appointments in the leadership of their BioTherapeutics Research and Development and Rinat units...
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
13 April 2015 | By Victoria White
Medivir and CRT have announced a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers...
Autophagy is a cellular homeostatic process regulating protein turnover as well as eliciting a stress response to starvation, chemical agents and pathogen infection. It has been implicated in the initiation and progression of several diseases, including neuro-degenerative disorders, Crohn’s disease, infections and cancer...
9 April 2015 | By Victoria White
Cellectis has established a new subsidiary, Cellectis, Inc. in New York City. The U.S. headquarters includes large state-of-the-art research laboratories...
7 April 2015 | By Victoria White
PhoreMost, a biopharmaceutical company focused on increasing diversity of novel therapeutics, has been founded to identify new druggable targets for cancer...
31 March 2015 | By Victoria White
Invectys has announced fundraising of 1.7 million euros from its original group of private investors, accelerating the clinical development of INVAC-1...
31 March 2015 | By Victoria White
Pfizer Inc. has announced that Charles Reay Mackay will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit...
31 March 2015 | By Victoria White
Merck Serono and Intrexon Corporation have announced an exclusive collaboration and license agreement to develop and commercialise CAR-T cancer therapies...
